Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Fosun to Start US Trial of COVID-19 Antibody Treatment
Fosun Pharma (SHA: 600196; HK: 02196) was granted US FDA approval to begin clinical tests of an investigational COVID-19 antibody treatment, HLX70. The trial will be conducted by Hengenix Biotech, the
The Phase I trial will evaluate the safety and pharmacokinetics of HLX70 in healthy volunteers. To date, Fosun has invested $2 million in the candidate, according to the company.
Henlius says it has three campuses working on developing biologics --
In March of this year, Fosun announced a $135 million agreement to develop and commercialize an mRNA COVID-19 vaccine in